Kymera Therapeutics (NASDAQ:KYMR) Earns Buy Rating from BTIG Research

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a report released on Tuesday,Benzinga reports. They presently have a $138.00 price target on the stock. BTIG Research’s price objective points to a potential upside of 77.61% from the company’s previous close.

A number of other analysts have also commented on the company. Barclays boosted their target price on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research report on Tuesday, January 27th. JPMorgan Chase & Co. boosted their price objective on Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Oppenheimer upped their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Truist Financial lifted their price target on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics has a consensus rating of “Buy” and an average price target of $117.00.

Kymera Therapeutics Stock Up 0.6%

NASDAQ:KYMR opened at $77.70 on Tuesday. Kymera Therapeutics has a twelve month low of $19.44 and a twelve month high of $103.00. The company has a fifty day moving average of $76.25 and a 200-day moving average of $60.47. The firm has a market capitalization of $5.59 billion, a P/E ratio of -21.64 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The company had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million. On average, analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bros. Advisors Lp Baker bought 2,005,813 shares of the stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $86.00 per share, for a total transaction of $172,499,918.00. Following the completion of the acquisition, the director directly owned 7,955,916 shares in the company, valued at approximately $684,208,776. This trade represents a 33.71% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.76, for a total transaction of $448,800.00. The SEC filing for this sale provides additional information. Insiders sold a total of 420,895 shares of company stock worth $37,778,351 in the last three months. 16.01% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Federated Hermes Inc. bought a new stake in Kymera Therapeutics in the third quarter worth about $31,622,000. China Universal Asset Management Co. Ltd. grew its position in shares of Kymera Therapeutics by 77.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after acquiring an additional 10,052 shares during the period. Frontier Capital Management Co. LLC increased its stake in shares of Kymera Therapeutics by 272.7% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after purchasing an additional 359,847 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Kymera Therapeutics by 26.3% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock worth $4,689,000 after purchasing an additional 22,392 shares during the period. Finally, Atika Capital Management LLC purchased a new position in Kymera Therapeutics in the second quarter valued at approximately $6,398,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.